/ISOFOL.ST
ISOFOL.ST Stock - Isofol Medical AB (publ)
Healthcare|BiotechnologySTO
$0.72+2.84%
+$0.02 (+2.84%) • Dec 23
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.24
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.73
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.80
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ISOFOL.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.72 – $0.73
TARGET (TP)$0.83
STOP LOSS$0.67
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.18
52W High$2.79
52W Low$0.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $721,000 | $12.80M | $22.41M | $37.12M |
| Gross Profit | $-38,734,000 | $-34,415,000 | $-165,707,000 | $-174,305,000 | $-162,416,000 |
| Gross Margin | N/A | -4773.2% | -1294.9% | -777.9% | -437.6% |
| Operating Income | $-47,209,000 | $-41,683,000 | $-167,460,000 | $-204,465,000 | $-186,494,000 |
| Net Income | $-43,488,000 | $-37,071,000 | $-159,793,000 | $-200,251,000 | $-188,992,000 |
| Net Margin | N/A | -5141.6% | -1248.7% | -893.7% | -509.2% |
| EPS | $-0.27 | $-0.23 | $-0.99 | $-1.59 | $-2.43 |
Company Overview
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ISOFOL.STBeat Rate
64%
Last 11 quarters
Avg Surprise
+21.3%
EPS vs Estimate
Beats / Misses
7/4
Last 12 quarters
Latest EPS
$-0.05
Q4 2025
EPS Surprise History
Q1 24
+56.0%
$-0.06vs$-0.13
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 19, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | $-0.05 | — | — |
Q3 2025 | Jul 18, 2025 | — | $-0.09 | — | — |
Q2 2025 | May 21, 2025 | — | $-0.08 | — | — |
Q1 2025 | Feb 19, 2025 | — | $-0.08 | — | — |
Q4 2024 | Nov 12, 2024 | — | $-0.07 | — | — |
Q3 2024 | Aug 21, 2024 | — | $-0.07 | — | — |
Q2 2024 | May 8, 2024 | — | $-0.05 | — | — |
Q1 2024 | Feb 20, 2024 | $-0.13 | $-0.06 | +56.0% | ✓ BEAT |
Q4 2023 | Nov 10, 2023 | $-0.12 | $-0.04 | +68.6% | ✓ BEAT |
Q3 2023 | Aug 22, 2023 | $-0.15 | $-0.05 | +69.9% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.19 | $-0.09 | +52.6% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.48 | $-0.16 | +66.7% | ✓ BEAT |
Q4 2022 | Nov 11, 2022 | $-0.32 | $-0.20 | +37.5% | ✓ BEAT |
Q3 2022 | Aug 23, 2022 | $-0.32 | $-0.33 | -3.1% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.31 | $-0.30 | +3.2% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.32 | $-0.38 | -18.8% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q3 2021 | Aug 24, 2021 | $-0.26 | $-0.48 | -84.6% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ISOFOL.ST
What is ISOFOL.ST's current stock price?
Isofol Medical AB (publ) (ISOFOL.ST) is currently trading at $0.72 per share. The stock has moved +2.84% today.
What is the analyst price target for ISOFOL.ST?
No analyst price targets are currently available for this stock.
What sector is Isofol Medical AB (publ) in?
Isofol Medical AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is ISOFOL.ST's market cap?
Isofol Medical AB (publ) has a market capitalization of $0.20 billion, making it a small-cap company.
Does ISOFOL.ST pay dividends?
No, Isofol Medical AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALZ.ST
Alzinova AB (publ)
$0.82
Mkt Cap: $0.1B
ANNX.ST
Annexin Pharmaceuticals AB (publ)
$19.00
Mkt Cap: $0.1B
BIOWKS.ST
Bio-Works Technologies AB (publ)
$2.25
Mkt Cap: $0.2B
CLS-B.ST
Clinical Laserthermia Systems AB (publ)
$7.00
Mkt Cap: $0.2B
ERMA.ST
Enorama Pharma AB (publ)
$2.30
Mkt Cap: $0.2B
INIT.ST
Initiator Pharma A/S
$2.93
Mkt Cap: $0.2B
IRLAB-A.ST
IRLAB Therapeutics AB (publ)
$1.97
Mkt Cap: $0.2B
KDEV.ST
Karolinska Development AB (publ)
$0.43
Mkt Cap: $0.1B
LIPUM.ST
Lipum AB (publ)
$14.55
Mkt Cap: $0.3B
XBRANE.ST
Xbrane Biopharma AB (publ)
$10.88
Mkt Cap: $0.1B
Explore stocks similar to ISOFOL.ST for comparison